Nwabudike Stanley Madu, Edwards Camille V, Akinboro Oladimeji, Quinn Kathryn, Sarosiek Shayna, Ko Naomi
Section of Hematology and Medical Oncology, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
Case Rep Hematol. 2018 Dec 13;2018:9249506. doi: 10.1155/2018/9249506. eCollection 2018.
Breast cancer is the most common cancer diagnosed in women worldwide. Over the years, breast cancer treatment has undergone revolutionary changes especially for women with hormone receptor positive metastatic disease. As a result, women are living longer with their disease, particularly in developed countries. The use of cyclin-dependent kinase (CDK) 4/6 inhibitors with antiestrogen therapy is a relatively new therapeutic option which has been shown to improve progression-free survival. Hematologic adverse events, most frequently neutropenia, are well-known side effects of CDK 4/6 inhibitors. However, to our knowledge, aplastic anemia has never been reported. We report a case of aplastic anemia in a patient with metastatic breast cancer treated with palbociclib after multiple prior lines of therapy.
乳腺癌是全球女性中诊断出的最常见癌症。多年来，乳腺癌治疗发生了革命性变化，尤其是对于激素受体阳性转移性疾病的女性。因此，患有这种疾病的女性寿命更长，尤其是在发达国家。细胞周期蛋白依赖性激酶（CDK）4/6抑制剂与抗雌激素疗法联合使用是一种相对较新的治疗选择，已被证明可改善无进展生存期。血液学不良事件，最常见的是中性粒细胞减少，是CDK 4/6抑制剂众所周知的副作用。然而，据我们所知，再生障碍性贫血从未被报道过。我们报告了一例转移性乳腺癌患者在接受多线先前治疗后使用哌柏西利治疗出现再生障碍性贫血的病例。
